-
1 Comment
Shanghai MicroPort Endovascular MedTech Co., Ltd is currently in a long term uptrend where the price is trading 34.7% above its 200 day moving average.
From a valuation standpoint, the stock is 362.1% more expensive than other stocks from the Healthcare sector with a price to sales ratio of 44.5.
Shanghai MicroPort Endovascular MedTech Co., Ltd's total revenue rose by 64.9% to $142M since the same quarter in the previous year.
Its net income has increased by 78.7% to $52M since the same quarter in the previous year.
Finally, its free cash flow grew by 182.2% to $67M since the same quarter in the previous year.
Based on the above factors, Shanghai MicroPort Endovascular MedTech Co., Ltd gets an overall score of 4/5.
| ISIN | CNE100003MJ5 |
|---|---|
| Sector | Healthcare |
| Industry | Medical Devices |
| Exchange | SHG |
| CurrencyCode | CNY |
| Dividend Yield | 2.3% |
|---|---|
| Market Cap | 12B |
| PE Ratio | 21.42 |
| Target Price | 148.57 |
| Beta | 0.23 |
Shanghai MicroPort Endovascular MedTech Co., Ltd. engages in the research and development, manufacturing, sale, and services of aortic, peripheral vascular, and tumor intervention devices in China and internationally. The company offers Fontus, a branched stent graft system in surgical operation; CRONUS, a stent graft system in surgical operation; Hector, a multi-branch thoracic stent graft system; Cratos and Castor, a branched aortic stent graft system; Talos, a thoracic stent graft system; and Hercules, a thoracic stent graft system with low profile delivery system. It also provides Minos, an abdominal aortic stent graft and delivery System; Aorfix, an endovascular device designed for treating abdominal aortic aneurysms; Altura, a device designed for the endovascular repair of abdominal aortic aneurysms; Aegis, a bifurcated aortic stent graft system; and L-REBOA, an aortic occlusion balloon catheter. In addition, the company offers Reewarm PTX, a drug coated balloon PTA catheter; ReeAmber, a PTA balloon dilatation catheter; Reewarm, a PTA balloon dilatation catheter; Ryflumen, a peripheral high-pressure balloon dilatation catheter; and CROWNUS, a peripheral stent system; HawkMaster, a detachable fibered embolization coils; HawkNest, a fibered embolization coils; Veryan BM3D, which is designed for the treatment of symptomatic de novo lesions in the native superficial femoral artery; Vflower, a venous stent system; SeaDragon, a PTA balloon dilatation catheter; Vewatch, a vena cava filter; Vepack, a snare retrieval kit; VeinPro, an endovenous radiofrequency closure system; Reflow-speX, a support catheter; and DEMANTOID, a peripheral vascular guide wire. Further, it provides Tipspear, a transjugular liver access set. Shanghai MicroPort Endovascular MedTech Co., Ltd. was incorporated in 2012 and is based in Shanghai, the People's Republic of China.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for 688016.SHG using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2026
